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Abstract
Objective: Iran as a developing country is in the transition phase, which might have a big impact on the Burden of Disease
and Injury (BOD). This study aims to estimate Burden of Disease and Injury (BOD) in Iran up to 2025 due to four broad cause
groups using Disability-Adjusted Life Year (DALY).
Methods: The impacts of demographic and epidemiological changes on BOD (DemBOD and EpiBOD) were assessed
separately. We estimated DemBOD in nine scenarios, using different projections for life expectancy and total fertility rate.
EpiBOD was modeled in two scenarios as a proportion of DemBOD, based on the extracted parameters from an
international study.
Findings: The BOD is projected to increase from 14.3 million in 2003 to 19.4 million in 2025 (95% uncertainty interval: 16.8,
21.9), which shows an overall increase of 35.3%. Non-communicable diseases (12.7 million DALY, 66.0%), injuries (4.6 million
DALY, 24.0%), and communicable diseases, except HIV/AIDS (1.8 million DALY, 9%) will be the leading causes of losing
healthy life. Under the most likely scenario, the maximum increase in disease burden due to DemBOD is projected to be
observed in HIV/AIDS and Non-communicable diseases (63.9 and 62.4%, respectively) and due to EpiBOD in HIV/AIDS
(319.5%).
Conclusion: It seems that in the following decades, BOD will have a sharp increase in Iran, mainly due to DemBOD. It seems
that communicable diseases (except HIV/AIDS) will have less contribution, and especially non-communicable diseases will
play a more significant role.
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Introduction
Burden of Disease (BOD) is a population health index which
measures the gap between current health status and an ideal
situation where one lives into old age in full health, free of disease
and disability, using Disability-Adjusted Life Year (DALY). The
DALY is a sum of years of life lost due to premature death (YLL)
and period lived with disabilities (YLD). Therefore, one DALY is
considered as one lost year of healthy life due to disability or death
[1].
Projection of future BOD can be used as evidence for health
policy makers to assess the nature and extent of health problems in
a population and set up plans for them [2–3]. Studies have been
carried out to project the Global Burden of Disease (GBD) [2,4].
In addition to GBD, several studies in developed countries such as
France, Australia, and Western Australia have also projected the
BOD [5–7]. No such study was found in developing countries,
which is likely due to various issues in different healthcare system
such as the inaccuracy or lack of death registration data, cause-of-
death information, periodical data on disease specific prevalence
and incidence, and finally, missing information regarding disability
and remission durations of each disease or injury [8–10].
In this study, we modeled BOD until 2025 in Iran and assessed
its changes between 2003 and 2025. Iran is a developing country
located in the Middle East with a population of more than 70
million people. The World Bank places it geographically in the
Middle East and North Africa and economically among upper-
mid income countries (Per Capita Gross National Income was US
$4590 in 2009) [11].
There are a few considerations in the estimation of BOD in
Iran. On the national level, there is only one estimation for BOD
[12]; therefore it is not easy to model its time-trend. Moreover, we
could not find any consistent information about the long-term
trend of many epidemiological indices which are usually used in
the modeling of BOD [2].
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Based on the above explanation, we tried to project the BOD in
Iran up to 2025. However, because of these limitations, we
assumed that the total changes in BOD are due to the impact of
demographic (changes in size and age-sex structure of a
population) and epidemiological (changes in the prevalence and
incidence of diseases and their risk factors) components.
Materials and Methods
To project the BOD in Iran in 2025 and its changes from 2003
up to 2025, due to the impact of demographic and epidemiological
factors, we performed our analysis in six steps which are outlined
briefly as follows:
1. We projected the population of Iran in 2025 in different
scenarios.
2. We derived the age, sex, and disease-specific DALY rates from
the first Iran’s National Burden of Disease (IRNBD) study in
2003 [12].
3. We applied the 2003 DALY rates [12] to the 2025 projected
population under different scenarios to compute the expected
DALY in 2025; Moreover, we subtracted the 2003 DALY from
this estimation to provide a measure of the impact of
demographic factors on the change in BOD between 2003
and 2025; we labeled this estimation as ‘‘DemBOD’’. It is
important to mention that 2003 DALY was computed based
on the incidence based YLD.
4. We calculated the ratio of changes in number of death due to
epidemiological and demographic components using the latest
projection of GBD (Epi/Demo) [2]; then, we applied directly
this ratio to the ‘‘DemBOD’’ to obtain a measure of the impact
of epidemiological factors on the change in BOD between 2003
and 2025; this estimate was labeled as ‘‘EpiBOD’’.
5. We summed up the estimates of ‘‘DemBOD’’ and ‘‘EpiBOD’’
to calculate the ‘‘total change’’ in BOD between 2003 and
2025.
6. We added the 2003 DALY to the ‘‘total change’’ to calculate
the DALY in 2025. Detailed descriptions of these steps are
given below:
Population Projections
To obtain population projections, the Spectrum software
(version 3.40) was applied. Nine scenarios were prepared by
trends and changes in two factors: Total Fertility Rate (TFR) as a
measure of fertility and Life Expectancy (LE) as a measure of
mortality. For each of these two factors three probable scenarios
were assumed (low, medium, and high TFR and LE).
The reported values for TFR and LE in 2010 according to the
WHO latest report on World Health Statistics [13] and the United
Nations Population Division (UNPD) projections [14] were used as
main input data for 2010, in all three scenarios, to prepare
consistent population projections. Their values for 2025 were
assumed as follows: for the medium scenario no limitations were
taken into account for 2025 and the software assumptions were
accepted. For the other two scenarios, the TFR and LE were
assumed to have approximately 60.5 children per women and 62
years change from their corresponding values in the medium
scenario for 2025, respectively. Thus the final values in low,
medium, and high scenarios in 2025 for TFR were 1.3, 1.8, and
2.3 children per women. These values for LE in men were 71.3,
73.3, and 75.3 years, and in women 74.7, 76.7, and 78.7,
respectively.
For the purpose of population projections, we assumed the
political and economical situation of Iran and its surrounding
countries to be stable, with minimum impact of natural disasters.
DALY Rates and Classification of Broad Cause Groups
The DALY rates per 100,000 population for each main cause
group were separately extracted for men and women (classified in
eight age groups) from IRNBD in 2003 [12]. In each age-sex
category, these rates were classified into four broad cause groups
based on the latest projection of GBD [2]. Hence, in this
projection cause groups were as follows: 1) HIV/AIDS, 2) Group
I: communicable diseases except HIV/AIDS, 3) Group II: non-
communicable diseases (NCDs), and 4) Group III: Injuries.
For each demographic scenario, the age-, sex-, and broad cause-
specific DALY rates were applied to the age- and sex- projected
population and DALY in 2025 expected only on changing
demography was obtained; then, the average value of each cause
group specific DALY was obtained in the total population in 2025
across all demographic scenarios.
To project the DemBOD attributable to each cause group, the
2003 DALY of each cause group was subtracted from its
corresponding average value in 2025 across all demographic
scenarios.
This projection was based on the assumption that age-sex-
specific DALY rates observed in 2003, will remain constant for the
entire projection period (from 2003–2025).
Projecting the Impact of Epidemiological Factors: Main
Scenarios
We used the impact of income on the BOD to project the
EpiBOD as well as 2025 DALY and considered two income
scenarios, based on the World Bank’s country classification. As
Iran’s income category has been recently upgraded, we considered
the World Bank’s 2009 and 2012 classifications as probable
scenarios. Moreover, we assumed the most likely apt scenario to
estimate Iran’s BOD to be the one when following its past peer
countries (lower-mid income countries) [15–16].
We separately calculated the Epi/Demo ratio for each cause
group by different economic scenarios [2]. For each cause group
by probable economic scenarios, we first applied Epi/Demo to the
DemBOD to project the EpiBOD. We summed the EpiBOD and
DemBOD to project the total change in BOD from 2003 to 2025
afterwards. Finally, the 2003 DALY were added to their
corresponding total change to project DALY in 2025.
In this approach, we assumed the Epi/Demo ratio to be time-
independent and directly applicable for possible changes in BOD.
Moreover, it was assumed that Iran’s BOD will follow a similar
pattern to that of the economic category.
We carried out all above steps on each cause group, but at the
end of each step aggregated them into one group (called total), for
presentation of the results. Moreover, all estimations were carried
out per 100,000 population as well.
Uncertainty Analysis
To evaluate the uncertainties in BOD, Monte Carlo method
was employed using Stata (Version 10 for Windows). For full
description of the modeling approach, please see Document S1.
Results
Trend of DemBOD between 2003 and 2025
Our population projections in 2025 foresee a substantial
population increase over the next two decades. The projected
population under the HH scenario (high TFR and high LE) was
Modeling Burden of Disease in Iran to 2025
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90.7 million, compared with the LL scenario (low TFR and low
LE) of 83.1 million, showing a difference of 8.3 percent; nearly
11% of population was more than 60 years in both scenarios
(Table S1). We observed that the DemBOD will be comparable
across all demographic scenarios in total (BOD in all four broad
cause groups) and in all cause groups, except Group I. In total
population, the lowest and highest values were in LL and HH
scenarios, respectively. The DemBOD attributed to Group I
followed a different pattern in different scenarios – It will increase
in high TFR scenarios and decrease in medium and low TFR
scenarios (Table S2).
Our results showed that the average DemBOD is projected to
increase in total and in all cause groups, except Group I. The total
DemBOD will increase 6.3 million DALY (95% uncertainty
interval [UI]: 6.1, 6.5). Regarding DemBOD attributed to Group
II, III, and HIV/AIDS, our projections showed an increase of
5.41, 1.10, and 0.04 million DALY, respectively. However, we
found a decrease of 0.24 million DALY in DemBOD attributed to
Group I (Figure 1).
Per 100,000 population, the DemBOD attributed to Group I
and III are projected to decrease (863 and 140 person-year,
respectively), while the DemBOD attributed to Group II and
HIV/AIDS are projected to increase (2066 and 21 person-year,
respectively). The DemBOD in total will increase 1085 person-
year (95% UI: 692, 1501).
Trend of EpiBOD between 2003 and 2025
Following the economical pattern of lower-mid income coun-
tries versus the upper-mid income countries, the impact of
EpiBOD will be more prominent in all cause groups and total.
The projected total BOD due the epidemiological variations will
decrease over time (between 0.93 and 1.23 million DALYs)
(Figure 2).
We observed that in lower-mid- and upper-mid- income
scenarios EpiBOD attributed to Groups I is projected to increase
(0.39 and 0.31 million DALYs, respectively); while the EpiBOD
attributed to Group II is projected to decrease (1.37 and 1.13
million DALYs, respectively).
The EpiBOD due to HIV/AIDS followed a different pattern; it
will increase 183,000 DALYs in lower-mid income scenario, and
decrease 110,000 DALYs in upper-mid income scenario. The
BOD attributed to Group III is projected to decrease (0.44 million
DALYs) in lower-mid income scenario and remain constant in
upper-mid income scenario.
Following the lower-mid income scenario, in 100,000 popula-
tion, the projected EpiBOD will decrease in Group II (524 person-
year), and increase in Groups I, Group III, HIV/AIDS, and total
(1439, 56, 110, and 1080 person-year, respectively).
Following the upper-mid income scenario, in 100,000 popula-
tion, the EpiBOD will decrease in Group II and HIV/AIDS (433
and 65 person-year, respectively), and increase in total and Group
I (629 and 1129 person-year, respectively), and remain constant in
Group III.
BOD in 2025 and its Changes from 2003
Our projection scenarios in forecasting the total changes in
BOD showed that the burden will increase in both lower-mid- and
upper-mid- income scenarios in total and all cause groups, except
HIV/AIDS. On the contrary, the projection of HIV/AIDS
burden showed different results; in the lower-mid income scenario
HIV/AIDS burden will have an increase of 219,000 while in
upper-mid income scenario will have a decrease of about 73,000
DALYs (Figure 3).
Per 100,000 population, the BOD attributed to Group III is
projected to decrease; while the BOD attributed to Group I,
Group II, and total are projected to increase in both income
scenarios. However, HIV/AIDS burden will increase to 132
person-years in lower-mid income scenario and decrease to 44 in
upper-mid income scenario (Figure 3).
Figure 1. Projected the changes in disease burden due to demographic variations in broad cause groups and total across all
demographic scenarios from 2003–2025. Results are classified in total population (A) and per 100,000 population (B). Vertical bars show the
95% uncertainty interval.
doi:10.1371/journal.pone.0076881.g001
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Our results showed that the total BOD will increase 35.3% from
2003 to 2025 in the most likely scenario. In this scenario, the
DemBOD will increase 43.9% and EpiBOD decrease 8.6%. The
total BOD will have an increase of 10.0% per 100,000 population;
the increasing impact of DemBOD and EpiBOD will be 5%.
Table 1 demonstrates the ratio of changes in BOD in each four
cause groups from 2003–2025 to their corresponding values in
2003 along with the contribution of DemBOD and EpiBOD.
Total DALY due to demographic and epidemiological factors
will increase from 14.35 million in 2003 to 19.42 million in 2025
(95% UI: 16.8.1, 21.9), an overall increase of 35.33%. The
probability of losing one DALY will rise from 0.21 in 2003 to 0.24
in 2025 (an overall increase of 3%). The projection of DALY
attributed to each broad cause group showed that Group II will be
the leading cause group for the BOD, and account for about 66%
of total BOD in 2025 (Figure 4 and 5).
Figure 2. Projected the changes in disease burden due to epidemiological components in broad cause groups and total. Results are
classified by Lower-Mid and Upper-Mid income scenarios from 2003 to 2025 in total population (A) and per 100,000 population (B). Vertical bars show
the 95% uncertainty interval.
doi:10.1371/journal.pone.0076881.g002
Figure 3. Projected the total changes in disease burden in broad cause groups and total. Results are classified by Lower-Mid and Upper-
Mid income scenarios from 2003 to 2025 in total population (A) and per 100,000 population (B). Vertical bars show the 95% uncertainty interval.
doi:10.1371/journal.pone.0076881.g003
Modeling Burden of Disease in Iran to 2025
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Discussion
Having used the best available data, we projected the BOD in
Iran by 2025. Our projections showed that the DALY for all
diseases and injuries will be 19.42 millions in 2025, predicting an
increase of 35.332% compared to the estimates of 2003.We
estimated that NCDs, injuries, and communicable diseases (except
HIV/AIDS) will be the leading cause of losing healthy life. By
comparison, the latest projection of GBD showed an increase of
3% in worldwide BOD in compare with the year 2002 [2].
The burden attributable to HIV/AIDS will considerably
increase to 280,000 in 2025, which is five times greater than the
estimate of 2003; its contribution will increase from 0.4% (in 2003)
to 1% (in 2025). Compatible with our findings, studies have shown
that HIV/AIDS will be one of the leading causes of DALY in
middle income countries by 2030 [2]. In Iran, the number of new
HIV cases has been on an upward trend since 1990 and it was
projected to increase until 2012; moreover, it was projected that
the number of HIV infected people will increase by the end of
2014 [17].
Our projections forecasted that the attributed BOD to Group I
will have a slight increase by 2025. It was about 1.6 million
DALYs in 2003 and will increase to 1.8 million DALY in 2025. Its
contribution to the total DALY will decrease 2.5% by 2025 (its
contribution to BOD was 11.5% in 2003).Other studies have also
projected that the burden of this group will decrease in the
upcoming years due to a recent decline in age-specific death rates
[2,4].
The burden due to Group II in 2025 is projected to be 1.5 times
greater than that in 2003 (8.7 million) mainly due to aging of
population. Moreover, its contribution to total BOD will be 5%
greater than that of 2003. It has been projected that the worldwide
BOD due to NCDs would increase from 50% (in 2002) to 57% (in
2030) [2]. Generally, most of NCDs such as cardio-vascular
diseases, cancers, and mental and behavioral disorders are real
health concerns nowadays and they have an increasing trend in
most part of the world [18]. Therefore, it seems health systems
have to develop long term and comprehensive plan to deal with
this situation.
The Group III disease burden is projected to increase from 3.97
(in 2003) to 4.63 million (in 2025). However, its contribution to
total BOD will decrease from 27.6% to 24.0% between 2003 and
2025 due to a major increase in the burden due to NCDs. Other
studies have also projected that this group’s burden will increase,
mostly because of the increasing number of deaths due to road
traffic accidents as a result of economic growth in low and mid-
income countries [2,4].
Our projection suggests that demographic components will
increase the DemBOD in all groups, except Group I. Their
maximum and minimum increasing impacts were observed in the
HH and LL scenarios, respectively. It seems that aging has
minimum impact in increasing DemBOD in different TFR
Table 1. Projected ratio of the impact of demographic, epidemiological, and total change on disease burden by 2025 to DALY in
2003 classified by broad cause groups (The most probable scenario).
In total population Per 100000 population
Demographic
components
Epidemiological
components
Total
changes
Demographic
components
Epidemiological
components Total changes
Group I 214.5 24.2 9.7 234.9 58.1 23.2
Group II 62.4 215.8 46.5 14.6 23.7 10.9
Group III 27.6 211.1 16.5 22.4 0.9 21.4
HIV/AIDS 63.9 319.5 383.4 25.6 128 153
doi:10.1371/journal.pone.0076881.t001
Figure 4. Projected the DALY in broad cause groups and total by 2025 (The most probable scenario). Panel A shows the 2025 BOD in
total population and panel B per 100,000 population.
doi:10.1371/journal.pone.0076881.g004
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scenarios and maximum DemBOD was observed in scenarios with
high life expectancy. However, the changes in TFR have more or
less comparable impact on DemBOD in different LE scenarios.
The finding showed a positive association between TFR and
DemBOD.
Regarding the impact of epidemiological components, we
projected that the changes in these factors will decrease the
BOD. Iran’s economic growth in recent decades is undeniable
[11]. This is associated with increasing the level of development
through education, changing people’s lifestyles, advances in
medical technology and improving preventive healthcare systems.
We believe that chronic diseases onset and their complications as
well as the disability burden accordingly could be decreased or
delayed. If these changes continue, it is probable that the amount
of decrease might be more than that of projected here.
Having compared the impact of EpiBOD and DemBOD, we
found that they will act in opposite directions. HIV/AIDS is
however an exception, in which both epidemiological and
demographic components will increase its burden. Further
findings suggest that the greatest increasing impact of demograph-
ic and epidemiological components may be observed in Group II
and HIV/AIDS, respectively.
According to WHO report, the LE of Iranian men has
increased from 61 years in 1989 to 70 years in 2009; the
corresponding numbers for women were 65 years and 75 years
[13,19]. UNPD projects LE of 73.3 and 77.3 years in men and
women by 2025, respectively [14]. Therefore, the impact of aging
on BOD will be comparable in both sexes. Moreover, recent
figures have shown a downward trend in TFR from five children
per women in 1989 to 1.7 in 2010 [13,19]. The UNPD data bank
also shows a decrease in the population growth rate in a way that it
is estimated to reach 0.51 by 2025 [14]. It seems that older Iranian
populations, due to longer LE and low TFR, will generate more
disability but less premature death; which is comparable with the
pattern in other countries [2,4–6,16,20].
These projections have been prepared using a simple approach,
with the least information available. In order to deal with the
shortage of information we assumed that the changes of
epidemiological components in Iran will follow its pattern in
other countries with similar socio-economical level. For this
purpose two scenarios were created, compatible with lower and
upper middle income countries.
Due to some limitations in the projection method, these
estimates should be interpreted with caution. The lack of historical
trend information (in risk factors, death rates, and DALY) made us
use the trends of other countries with similar socio-economical
level. However, we took these uncertainties into account in our
Monte-Carlo analysis.
In addition, disaggregation of DALY by YLL and YLD was not
assessed due to lack of valid long-term information about the
mortality and morbidity, incidence and prevalence of main
diseases in Iran. Besides, baseline DALY rates in this study were
computed using ‘‘incidence YLD’’ in 2003, hence, our results may
need adjustments in order to be used for health policy and
planning. Since this study was the first of its kinds in Iran and due
to scarcity of data, we could not assess the trend of BOD in
different diseases such cancers, cardio-vascular diseases, or
respiratory diseases, etc. However, it is very important issue which
has to be addressed in future studies.
It seems that the BOD will increase around 35% in Iran in the
next two decades, mainly due to aging. Our model shows that
NCDs will be the leading cause of DALY in 2025 in Iran;
however, the increasing trend of BOD due to HIV/AIDS will be
important. As might be expected, we found that BOD due to
Group I (other infectious diseases, malnutrition, infant and
maternal mortality rates) will have a very slight increase.
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